Related Experiment Video
Updated: Jul 17, 2026
08:47
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
US FDA perspective on regulatory issues affecting circulatory assist devices
Wolf Sapirstein1, Eric Chen, Julie Swain
1Division of Cardiovascular Devices, Office of Device Evaluation, Center for Devices and Radiological Health, US FDA, Rockville, MD 20850, USA. wys@cdrh.fda.gov
Expert Review of Medical Devices
|February 7, 2007
Summary
Mechanical circulatory support devices, including Ventricular Assist Devices and Total Artificial Hearts, have advanced significantly. These systems now offer improved circulatory support for heart failure patients, with evolving regulatory considerations.
Area of Science:
- Biomedical Engineering
- Cardiovascular Medicine
- Regulatory Science
Background:
- Mechanical circulatory support systems have seen rapid advancements since FDA approval.
- Devices evolved from external to totally implanted systems, improving cardiac support.
- Approved devices include Ventricular Assist Devices and Total Artificial Hearts.
Purpose of the Study:
- To review the US FDA's regulatory perspective on mechanical circulatory support systems.
- To discuss the evolution and expanding applications of these devices.
- To address challenges in ensuring safety and effectiveness for new technologies.
Main Methods:
- Review of FDA approvals and technological advancements in mechanical circulatory support.
- Analysis of clinical study outcomes demonstrating improved homeostatic adequacy.
- Examination of regulatory challenges posed by novel pump mechanisms and expanded patient populations.
Main Results:
- Mechanical circulatory support devices have progressed from short-term support to bridging-to-transplant and destination therapy.
- Technological improvements have led to more compact and effective devices.
- New pump technologies present regulatory hurdles for safety and efficacy assurance.
Conclusions:
- Mechanical circulatory support technology has significantly improved outcomes for heart failure patients.
- The FDA faces evolving challenges in regulating innovative mechanical circulatory support devices.
- Ensuring safety and effectiveness is paramount for expanding the use of these critical healthcare technologies.
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...